ONWARD MEDICAL BV EO -12 Market Cap ($167.86 Million)
Market Cap & Net Worth: ONWARD MEDICAL BV EO -12 (63E)
ONWARD MEDICAL BV EO -12 market cap. ONWARD MEDICAL BV EO -12 (F:63E) has a market capitalization of $167.86 Million (€143.58 Million) as of November 4, 2026. Listed on the F stock exchange, this Germany-based company holds position #17055 globally and #1612 in its home market, demonstrating a -0.24% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ONWARD MEDICAL BV EO -12's stock price €2.07 by its total outstanding shares 69528511 (69.53 Million). Also see 63E cash flow metrics for how efficiently the company converts equity into cash flow.
ONWARD MEDICAL BV EO -12 Market Cap History (2021–2026)
ONWARD MEDICAL BV EO -12 market cap history from 2021 to 2026. Data shows change from $812.05 Million to $157.86 Million (-29.70% CAGR). Check ONWARD MEDICAL BV EO -12 stock price for real-time trading data and today's change.
ONWARD MEDICAL BV EO -12 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ONWARD MEDICAL BV EO -12's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore 63E year-over-year net asset growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
93.33x
ONWARD MEDICAL BV EO -12's market cap is 93.33 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $503.16 Million | $104.00K | -$32.77 Million | 4838.09x | N/A |
| 2023 | $239.79 Million | $68.00K | -$36.18 Million | 3526.38x | N/A |
| 2024 | $471.46 Million | $229.00K | -$35.73 Million | 2058.78x | N/A |
| 2025 | $352.78 Million | $3.78 Million | -$41.79 Million | 93.33x | N/A |
Competitor Companies of 63E by Market Capitalization
Companies near ONWARD MEDICAL BV EO -12 in the global market cap rankings as of November 4, 2026. Also see how large is ONWARD MEDICAL BV EO -12's balance sheet for a full breakdown of the balance sheet.
Key companies related to ONWARD MEDICAL BV EO -12 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #372 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #411 globally with a market cap of $69.05 Billion USD ( AU$97.59 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #497 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $553.15 |
| #372 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $961.26 |
| #411 | CSL Ltd | AU:CSL | $69.05 Billion | AU$201.16 |
| #497 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $220.83 |
Market Capitalization of ONWARD MEDICAL BV EO -12 (2021–2026)
Market capitalization of ONWARD MEDICAL BV EO -12 from 2021 to today. Between 2021 and today, ONWARD MEDICAL BV EO -12's market cap moved from $812.05 Million to $ 157.86 Million, with a yearly change of -29.70%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €157.86 Million | -55.25% |
| 2025 | €352.78 Million | -25.17% |
| 2024 | €471.46 Million | +96.61% |
| 2023 | €239.79 Million | -52.34% |
| 2022 | €503.16 Million | -38.04% |
| 2021 | €812.05 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of ONWARD MEDICAL BV EO -12 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $167.86 Million USD |
| MoneyControl | $167.86 Million USD |
| MarketWatch | $167.86 Million USD |
| marketcap.company | $167.86 Million USD |
| Reuters | $167.86 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ONWARD MEDICAL BV EO -12
Onward Medical N.V., a medical technology company, develops and commercializes therapies to enable functional recovery for people with Spinal Cord Injury (SCI). The company engages in developing ARCEX, a technology to enhance hand strength and sensation for individuals with SCI; ARCIM, a spinal cord stimulation system designed to address blood pressure instability and other symptoms in people wit… Read more